KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Work In Process (2016 - 2019)

Pfizer (PFE) has disclosed Work In Process for 11 consecutive years, with $5.2 billion as the latest value for Q1 2019.

  • Quarterly Work In Process rose 15.54% to $5.2 billion in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $5.2 billion through Mar 2019, up 15.54% year-over-year, with the annual reading at $4.7 billion for FY2018, 20.29% up from the prior year.
  • Work In Process for Q1 2019 was $5.2 billion at Pfizer, up from $4.7 billion in the prior quarter.
  • The five-year high for Work In Process was $5.2 billion in Q1 2019, with the low at $3.4 billion in Q1 2015.
  • Average Work In Process over 5 years is $4.2 billion, with a median of $4.0 billion recorded in 2016.
  • The sharpest move saw Work In Process rose 21.06% in 2015, then decreased 6.0% in 2016.
  • Over 5 years, Work In Process stood at $3.9 billion in 2015, then fell by 6.0% to $3.7 billion in 2016, then rose by 5.74% to $3.9 billion in 2017, then increased by 20.29% to $4.7 billion in 2018, then rose by 10.23% to $5.2 billion in 2019.
  • According to Business Quant data, Work In Process over the past three periods came in at $5.2 billion, $4.7 billion, and $4.8 billion for Q1 2019, Q4 2018, and Q3 2018 respectively.